Legacy Private Trust Co. Buys 122 Shares of Amgen Inc. (NASDAQ:AMGN)

Legacy Private Trust Co. lifted its stake in Amgen Inc. (NASDAQ:AMGN) by 1.8% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,932 shares of the medical research company’s stock after buying an additional 122 shares during the quarter. Legacy Private Trust Co.’s holdings in Amgen were worth $2,234,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Hershey Financial Advisers LLC bought a new stake in Amgen during the 2nd quarter valued at approximately $30,000. nVerses Capital LLC purchased a new position in Amgen during the 2nd quarter valued at approximately $31,000. Bbjs Financial Advisors LLC purchased a new position in Amgen during the 2nd quarter valued at approximately $33,000. FSA Wealth Management LLC grew its holdings in Amgen by 182.0% during the 1st quarter. FSA Wealth Management LLC now owns 141 shares of the medical research company’s stock valued at $40,000 after buying an additional 91 shares in the last quarter. Finally, Western Pacific Wealth Management LP grew its holdings in Amgen by 27.6% during the 1st quarter. Western Pacific Wealth Management LP now owns 162 shares of the medical research company’s stock valued at $46,000 after buying an additional 35 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

NASDAQ AMGN traded up $1.16 on Tuesday, hitting $318.61. 59,338 shares of the company’s stock traded hands, compared to its average volume of 2,476,095. The company has a current ratio of 1.26, a quick ratio of 0.89 and a debt-to-equity ratio of 9.64. Amgen Inc. has a 1-year low of $249.70 and a 1-year high of $346.85. The firm’s 50-day moving average price is $327.28 and its two-hundred day moving average price is $309.48. The firm has a market capitalization of $170.91 billion, a PE ratio of 45.35, a P/E/G ratio of 2.98 and a beta of 0.61.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, August 6th. The medical research company reported $4.97 EPS for the quarter, missing the consensus estimate of $5.01 by ($0.04). Amgen had a net margin of 10.12% and a return on equity of 161.72%. The business had revenue of $8.39 billion for the quarter, compared to analyst estimates of $8.35 billion. During the same quarter in the previous year, the firm posted $5.00 earnings per share. The business’s revenue was up 20.1% on a year-over-year basis. As a group, analysts expect that Amgen Inc. will post 19.49 EPS for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were paid a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a yield of 2.82%. The ex-dividend date of this dividend was Friday, August 16th. Amgen’s payout ratio is 128.57%.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. TD Cowen raised their price target on Amgen from $360.00 to $381.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Robert W. Baird reiterated an “underperform” rating and issued a $215.00 target price on shares of Amgen in a report on Wednesday, September 25th. Barclays lifted their target price on Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a report on Monday. Oppenheimer reiterated an “outperform” rating and issued a $380.00 target price on shares of Amgen in a report on Wednesday, August 7th. Finally, Bank of America upped their price target on shares of Amgen from $325.00 to $330.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, eleven have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Amgen currently has an average rating of “Moderate Buy” and a consensus target price of $326.30.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.